Director sale: Arcutis Biotherapeutics (NASDAQ: ARQT) plans to sell 684 shares

Rhea-AI Filing Summary

Arcutis Biotherapeutics filing reports an intended sale of 684 shares of Common Stock related to restricted stock vesting on 05/01/2026. The filing also lists prior sales by Patrick Burnett of 9,794 shares on 02/04/2026 for $252,748.08 and 6,287 shares on 03/02/2026 for $158,319.86.

Insights

Securities Compliance Analyst

Routine insider sale notice under Rule 144; no new material event disclosed.

This Form 144 reports a planned sale of 684 shares tied to restricted stock vesting and cites recent open-market dispositions by the same insider. The filing lists broker details (Merrill Lynch) and sale amounts for prior transactions.

These disclosures are procedural: they document intent to sell and prior transactions. Subsequent Form 4 or transaction confirmations would show execution details and actual proceeds.

Key Figures

Planned sale: 684 shares Prior sale 1: 9,794 shares Prior sale 2: 6,287 shares +1 more

4 metrics

Planned sale 684 shares restricted stock vesting on 05/01/2026

Prior sale 1 9,794 shares sold 02/04/2026 for $252,748.08

Prior sale 2 6,287 shares sold 03/02/2026 for $158,319.86

Broker Merrill Lynch listed broker at 8890 Lyra Drive, Columbus, OH

Key Terms

Form 144, Restricted Stock Vesting, Merrill Lynch

3 terms

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Common | 05/01/2026 | Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Merrill Lynch other

"Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	684	16149.65	124033382	05/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			684	05/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	02/04/2026	9794	252748.08
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	03/02/2026	6287	158319.86

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ARQT Form 144 disclose?

It discloses a planned sale of 684 shares tied to restricted stock vesting on 05/01/2026. The filing also lists prior sales by Patrick Burnett of 9,794 shares (02/04/2026) and 6,287 shares (03/02/2026) with stated proceeds.

Who is the reported seller in the ARQT filing?

The filing lists Patrick Burnett as the reporting person and shows prior sales in his name. The 684-share vesting item references Arcutis Biotherapeutics restricted stock vesting with Merrill Lynch as broker.

How many shares were sold previously by the insider?

Prior reported sales were 9,794 shares on 02/04/2026 and 6,287 shares on 03/02/2026. The reported gross proceeds for those sales were $252,748.08 and $158,319.86 respectively.

Does the Form 144 confirm the sale of the 684 shares?

No—Form 144 reports the intention to sell securities (e.g., due to vesting) rather than confirming execution. Execution and final amounts would appear in subsequent transaction reports or broker confirmations.